Karyopharm Therapeutics (NASDAQ:KPTI) – Investment analysts at Jefferies Group lowered their Q2 2018 earnings estimates for Karyopharm Therapeutics in a research note issued on Tuesday, May 15th. Jefferies Group analyst M. Raycroft now forecasts that the company will post earnings per share of ($0.77) for the quarter, down from their prior estimate of ($0.62). Jefferies Group has a “Buy” rating on the stock. Jefferies Group also issued estimates for Karyopharm Therapeutics’ Q3 2018 earnings at ($0.71) EPS, Q4 2018 earnings at ($0.78) EPS, FY2018 earnings at ($3.03) EPS, FY2019 earnings at ($2.66) EPS, FY2020 earnings at ($1.05) EPS, FY2021 earnings at ($0.74) EPS and FY2022 earnings at $0.73 EPS.
Get Karyopharm Therapeutics alerts:
Karyopharm Therapeutics (NASDAQ:KPTI) last released its earnings results on Thursday, May 10th. The company reported ($0.78) earnings per share for the quarter, missing the consensus estimate of ($0.67) by ($0.11). The company had revenue of $10.00 million for the quarter, compared to analyst estimates of $4.59 million.
Several other research firms have also recently weighed in on KPTI. HC Wainwright reissued a “buy” rating and issued a $30.00 target price on shares of Karyopharm Therapeutics in a research note on Thursday. Zacks Investment Research raised shares of Karyopharm Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday. BidaskClub raised shares of Karyopharm Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday. Canaccord Genuity lifted their price objective on shares of Karyopharm Therapeutics from $18.00 to $22.00 and gave the stock a “buy” rating in a research report on Monday, March 12th. Finally, Cantor Fitzgerald set a $18.00 price objective on shares of Karyopharm Therapeutics and gave the stock a “buy” rating in a research report on Thursday, March 15th. Two research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the stock. Karyopharm Therapeutics has a consensus rating of “Buy” and a consensus price target of $21.10.
Karyopharm Therapeutics opened at $19.08 on Friday, Marketbeat reports. Karyopharm Therapeutics has a 1-year low of $18.33 and a 1-year high of $18.89.
In other news, CEO Michael Kauffman sold 10,000 shares of the business’s stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $14.79, for a total value of $147,900.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Mansoor Raza Mirza sold 2,500 shares of the business’s stock in a transaction dated Monday, March 12th. The shares were sold at an average price of $17.01, for a total transaction of $42,525.00. Following the completion of the sale, the director now directly owns 2,500 shares of the company’s stock, valued at approximately $42,525. The disclosure for this sale can be found here. In the last three months, insiders sold 67,000 shares of company stock valued at $1,021,320. 14.71% of the stock is currently owned by company insiders.
Hedge funds have recently bought and sold shares of the stock. Teacher Retirement System of Texas acquired a new position in Karyopharm Therapeutics in the fourth quarter valued at about $115,000. MetLife Investment Advisors LLC acquired a new position in Karyopharm Therapeutics in the fourth quarter valued at about $146,000. Two Sigma Investments LP raised its stake in Karyopharm Therapeutics by 76.8% in the fourth quarter. Two Sigma Investments LP now owns 24,220 shares of the company’s stock valued at $233,000 after purchasing an additional 10,520 shares in the last quarter. UBS Group AG raised its stake in Karyopharm Therapeutics by 761.8% in the first quarter. UBS Group AG now owns 19,632 shares of the company’s stock valued at $264,000 after purchasing an additional 17,354 shares in the last quarter. Finally, DekaBank Deutsche Girozentrale acquired a new position in Karyopharm Therapeutics in the first quarter valued at about $269,000. 62.65% of the stock is owned by institutional investors and hedge funds.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor(KPT-330), which is in Phase 2b clinical study in treatments of refractory multiple myeloma; Phase 1b/2 clinical study in combination with backbone treatments for multiple myeloma patients; Phase 2b clinical study in diffuse large B-cell lymphoma; Phase 3 clinical trial in combination with Velcade (bortezomib) and dexamethasone for multiple myeloma patients; and Phase 2/3 clinical study in liposarcoma.